Hussman Strategic Advisors Inc. Purchases Shares of 31,500 Tarsus Pharmaceuticals, Inc. $TARS

Hussman Strategic Advisors Inc. acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 31,500 shares of the company’s stock, valued at approximately $1,872,000.

Several other hedge funds have also recently made changes to their positions in TARS. TFG Asset Management GP Ltd increased its position in Tarsus Pharmaceuticals by 40.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after purchasing an additional 71,530 shares during the period. Capricorn Fund Managers Ltd purchased a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth about $14,264,000. Allianz Asset Management GmbH bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $227,000. Jump Financial LLC increased its position in shares of Tarsus Pharmaceuticals by 385.9% during the second quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock valued at $9,606,000 after buying an additional 188,317 shares during the period. Finally, Norges Bank bought a new position in Tarsus Pharmaceuticals in the second quarter worth about $19,095,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on TARS shares. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group restated a “neutral” rating and set a $51.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th. Mizuho assumed coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, Barclays assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $79.86.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the transaction, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 0.3%

TARS stock opened at $68.15 on Wednesday. The business has a 50 day moving average of $78.32 and a 200 day moving average of $65.11. The firm has a market cap of $2.89 billion, a PE ratio of -33.74, a price-to-earnings-growth ratio of 0.98 and a beta of 0.59. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The firm had revenue of $118.70 million for the quarter, compared to analysts’ expectations of $114.22 million. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.